Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$234.38 USD

234.38
566,922

+5.27 (2.30%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $234.35 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

LabCorp (LH) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sales rebound in the base business for Diagnostics business and strong drug development orders are expected to have driven LabCorp's (LH) second-quarter performance.

Labcorp (LH) Completes Strategic Deal With Jefferson Health

by Zacks Equity Research

Labcorp's (LH) agreement with Jefferson to build academic collaborations around teaching and developing innovative tests.

Labcorp (LH) Inks Asset Acquisition Deal With Legacy Health

by Zacks Equity Research

Labcorp's (LH) new agreement with Legacy Health will broaden access to its Diagnostics capabilities and improve services.

Should Value Investors Buy Laboratory Corp. of America (LH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LabCorp (LH) Partners With Forge Biologics for Gene Therapies

by Zacks Equity Research

LabCorp's (LH) latest partnership will significantly assist patients gain access to cutting-edge, potentially life-saving medication.

Labcorp (LH) Announces Completion of the Fortrea Spin-off

by Zacks Equity Research

Labcorp (LH) completes the planned spin-off of Fortrea to operate as an independent clinical development business.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

by Zacks Equity Research

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

LabCorp (LH) Provides Update on Planned Spinoff of Fortrea

by Zacks Equity Research

After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.

LabCorp (LH) Expands Precision Oncology With Biopsy Test

by Zacks Equity Research

The addition of Labcorp Plasma Focus marks a pivotal step in the expansion of LabCorp's (LH) suite of precision oncology tests.

Why Is LabCorp (LH) Down 2.7% Since Last Earnings Report?

by Zacks Equity Research

LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

LabCorp (LH) Expands Laboratory Relationship With New Pact

by Zacks Equity Research

LabCorp's (LH) recent partnership will expand healthcare access, offer advanced diagnostic tools and guarantee that both patients and doctors can afford the treatments they get.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays

by Zacks Equity Research

LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.

The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp

by Zacks Equity Research

BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.

LabCorp (LH) Q1 Earnings Miss Estimates, Margins Decline

by Zacks Equity Research

The decline in COVID-19 PCR and antibody testing sales, the severe foreign exchange headwind and inflationary pressure hurt LabCorp's (LH) business performance in Q1.

Compared to Estimates, LabCorp (LH) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for LabCorp (LH) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

LabCorp (LH) Misses Q1 Earnings Estimates

by Zacks Equity Research

LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Ongoing sales rebound in the base business for both Diagnostics and Drug Development segments is likely to have benefited LabCorp (LH) in Q1.

LabCorp (LH) Expands Colon Cancer Test Access With New Pact

by Zacks Equity Research

LabCorp's (LH) at-home collection kit will offer patients an additional and easier option to get screened for colon cancer.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by strength in its Drug Development business.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

LabCorp (LH) Focuses on High-Growth Areas Amid Currency Woe

by Zacks Equity Research

In its efforts to expand further, LabCorp (LH) is focusing more on high-growth opportunity areas such as neurodegenerative, autoimmune and liver disease as well as cell and gene therapy.

The Zacks Analyst Blog Highlights TotalEnergies, America Movil, Palo Alto Networks, Manulife Financial and Laboratory Corporation of America

by Zacks Equity Research

TotalEnergies, America Movil, Palo Alto Networks, Manulife Financial and Laboratory Corporation of America are included in this Analyst Blog.